An In-Depth Review of Interstitial Lung Diseases: Epidemiology, Pathogenesis, and Clinical Management
OthersPage Navigation
Introduction
Interstitial lung diseases (ILDs) represent a heterogeneous group of disorders characterized by various forms of interstitial lung pathology. This article provides an in-depth review of the epidemiology, pathogenesis, and clinical management of ILDs.
Epidemiology
ILDs are relatively rare, with an estimated prevalence of 30-50 cases per 100,000 individuals. The incidence increases with age, particularly among those above 60 years. Certain occupations and environmental exposures, such as mining, farming, and bird handling, are associated with a higher risk of developing ILDs.
Pathogenesis
The pathogenesis of ILDs is complex and multifactorial, often involving a combination of genetic predisposition, environmental exposures, and immune dysregulation. The common pathological feature is the accumulation of inflammatory and fibrotic cells in the interstitial spaces, leading to progressive scarring and architectural distortion of the lung parenchyma.
Clinical Management
The management of ILDs is challenging due to their progressive nature and lack of curative treatments. The mainstay of therapy is immunosuppression, aimed at reducing inflammation and fibrosis. Lung transplantation remains the only definitive treatment for severe, end-stage ILDs. Recent advances in targeted therapies, such as antifibrotic drugs, have shown promise in slowing disease progression.
Conclusion
ILDs are a diverse group of disorders with complex pathogenesis and challenging management. Understanding the epidemiology and pathogenesis can aid in early detection and intervention. Further research is needed to develop more effective treatments and improve the prognosis of patients with ILDs.
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge